The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.
Cancer biotech Viracta Therapeutics has closed its doors, laying off all employees and winding down operations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback